Q2 STOCKS TO BUY

CytomX, Esperion, Nektar Therapeutics News Today

CytomX Therapeutics Inc, Esperion Therapeutics Inc, and Nektar Therapeutics are in the news today

Mar 20, 2017 at 10:02 AM
facebook X logo linkedin


Stocks are flat in the wake of the G-20 summit, which signaled a potential turn toward protectionism. Among stocks in focus are drugmakers CytomX Therapeutics Inc (NASDAQ:CTMX), Esperion Therapeutics Inc (NASDAQ:ESPR), and Nektar Therapeutics (NASDAQ:NKTR), Here's a quick roundup of the headlines moving shares of CTMX, ESPR, and NKTR -- the top three percentage gainers on the Nasdaq, at last check.

CytomX Stock Sizzles on Bristol-Myers Squibb Deal

CTMX shares are on fire, after the company extended its worldwide collaboration with Bristol-Myers Squibb Co (NYSE:BMY). With CytomX Therapeutics Inc in line to receive $200 million upfront, the stock has soared nearly 30% this morning to $19.71, and hit an annual high of $20.02. While the brokerage crowd has yet to weigh in on the expanded deal with BMY, CTMX has already received plenty of upbeat coverage. Specifically, 75% of analysts rate the stock a "strong buy," without a single "sell" recommendation on the books.

Esperion Explodes on FDA Nod

ESPR announced the U.S. Food and Drug Administration (FDA) has confirmed a regulatory pathway to approval for the drugmaker's heart drug. Not surprisingly, the stock has surged, up 53.3% at $36.28 -- and fresh off an annual high of $37.16 -- recovering from Friday's 20% fall. In fact, Esperion Therapeutics Inc shares have more than doubled in value on a year-over-year basis. One group potentially getting burned today is short sellers. Nearly 32% of ESPR's float is dedicated to these bearish bets, most of which are likely to be underwater following the bull gap.

Successful Study Sets Off Nektar Shares

NKTR is blasting off, as well, gapping up 28.6% to trade at $19.98, and just off a 10-year high of $20.29, after the company's opioid painkiller succeeded in a late-stage study. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), traders have been betting bullishly on the Nektar Therapeutics. The stock's 10-day call/put volume ratio sits at a top-heavy 20.20, ranking just 7 percentage points from an annual high.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter